期刊文献+

联合应用胺碘酮与替米沙坦治疗阵发性心房颤动125例临床观察 被引量:2

Clinical Observations of Amiodaronein and Telmisartan in Treating 125 Cases of Paroxysm Atrial Fibrillation
暂未订购
导出
摘要 目的:评价胺碘酮与替米沙坦联合应用治疗阵发性心房颤动的临床疗效。方法:将阵发性房颤患者(125例)随机分为胺碘酮治疗组(63例)和胺碘酮+替米沙坦组(62例)。首次治疗后,进行16个月随访。比较两组治疗后4,8,12,16个月的窦性心律维持率和治疗前、治疗后8,12,16个月的左房前后径。结果:治疗后4个月,胺碘酮治疗组窦性心律维持率为88.5%,与胺碘酮加替米沙坦治疗组(90.2%)比较无统计学差异(P>0.05)。治疗后8,12,16个月,胺碘酮治疗组窦性心律维持率分别为67.2%,62.3%,59.0%,胺碘酮加替米沙坦治疗组分别为88.3%,86.7%,83.3%,两组差异均有统计学意义(P<0.01)。而治疗12个月后,胺碘酮治疗组左心房前后径明显大于胺碘酮加替米沙坦治疗组(P<0.05)。结论:胺碘酮与替米沙坦联合治疗组患者的窦性心律维持率高于单纯胺碘酮治疗组,联合用药还可有效控制左心房扩大。 Objective: To investigate the effect of combination of telmisartan and amiodaronein in patients with paroxysm atrial fibrillation . Methods: 125 patients with paroxysmal atrial fibrillation were randomly divided into 2 groups : Groupl (amiondarone group , n = 63) and group 2 (telmisartan and amiodaronein group, n = 62) .After 16 months follow up, the maintenance rate of sinus rhythm was measured in the fourth, eighth, twelfth, sixteenth months , and the left atrail diameter was measured before treatment and eighth months after the treatment . Results: There was no difference between group I and group 2 in the fourth month. The maintenanee rate of sinus rhythm group was 67.2 %, 62.3 %, 59.0 % in the eighth, twelth, sixteenth months, and the rate in the group 2 was 88.3 %, 86.7 %, 83.3 %. they both had significant difference (P 〈 0.05). Conclusion the combination of telmisartan and amiodaronein is more effective than amiodarone alone for sinus rhythm maintenance , and may restrain the enlargement of the left atrium.
作者 赵贵明 蒋卉
出处 《内蒙古医学杂志》 2009年第2期144-146,共3页 Inner Mongolia Medical Journal
关键词 胺碘酮 替米沙坦 心房颤动 Amiodarone Telmisartan Atria fibrillation
  • 相关文献

参考文献8

  • 1Pedersen OD, Bagger H, Kober L, et al. Randolapril Reduces the Incidence of Atrial Fibrillation After Acute Myocardial Infarction in Patients With Left Ventrieular Dysfunction [ J ]. Circulation, 1999,100(4) : 376 - 380.
  • 2Wu L, Rajamani S, Shryock JC, et al. Augmentation of late sodium current unmasks the proarrhythmlc effects of amiodarone[J]. Cardiovasc Res, 2008 , 77(3) :481 - 488.
  • 3The AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug[J]. J Am Coil Cardiol, 2003, 42(1) : 20 - 29.
  • 4Goette A, Arndt M, Roeken C, et al. Regulation of angiotensin Ⅱ receptor subtypes during atrial fibrillation in humans[J]. Circulation, 2008 , 101(23) :2 678 - 3 681.
  • 5Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin Ⅱ type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation [J ]. J Am Coil Cardiol, 2003 , 41 ( 12 ) : 2 197-2204.
  • 6Hideko N, Koickiro K, Hidenori U. Angiotensin Ⅱ antagonist prevents electrical remodeling in atriak fibriUation [ J ]. Circulation, 2004, 101(22):2 612- 2 617.
  • 7Goette A, Schotten U. Inhibition of angiotensin Ⅱ type Ⅰ receptors reduces atrial stunning and spontaneous echo contrast after electrical cardioversion of atrial fibriUation[J ]. Eur Heart J, 2006, 27(17):2 034-2 035.
  • 8Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long- lasting persistent atrial fibrillation: a prospective and randomized study[J]. Circulation, 2002,106(3) : 331 - 336.

同被引文献24

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部